NPI 1013410380: Open Payments
NPI 1013410380. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$151 in 8 payments from 6 companies in 2025. Trend: 2023 $275 · 2024 $136 · 2025 $151
Food & beverage: $151
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $69 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Novo Nordisk Inc | 1 | $15 |
| PFIZER INC. | 1 | $14 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
Products named: VRAYLAR, UBRELVY, TRELEGY ELLIPTA, AIRSUPRA, Wegovy, PREVNAR 20, Kerendia.
